Related Experiment Video
Updated: Jul 5, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Rationale of treatment recommendations in the 2023 ESH hypertension guidelines
Giuseppe Mancia1, Mattias Brunström2, Michel Burnier3
1University of Milano-Bicocca, Milan, Italy.
Insights
No findings available for this study. Further research is needed to determine the key insights and implications.
Area of Science:
- No specific area of science was identified in the provided abstract.
Background:
- No background information was available in the provided abstract.
Discussion:
- No discussion points were available in the provided abstract.
Key Insights:
- No key insights could be extracted from the provided abstract.
Outlook:
- No future outlook could be determined from the provided abstract.
No abstract available in PubMed .
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension and Regulation of Blood Pressure
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pre-Procedural Guidelines for Assessing Blood Pressure

